Skip to content

A randomized controlled study of blood flow restriction combined with moderate intensity aerobic training to improve lipid deposition in metabolic related fatty liver disease

A randomized controlled study of blood flow restriction combined with moderate intensity aerobic training to improve lipid deposition in metabolic related fatty liver disease

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084927
Enrollment
Unknown
Registered
2024-05-28
Start date
2024-06-07
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MAFLD

Interventions

BFR-AE :8 weeks, 3 times/week, 40 minutes/session of blood flow restriction combined with moderate-intensity aerobic training
AE :8 weeks, 3 sessions/week, 40 minutes of simple moderate-intensity aerobic training

Sponsors

Friendship Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Diagnostic criteria based on the international expert consensus profile of the new definition of MASLD (2) MRI-PDFF showed steatosis =8% (3) Age 18-80 years old

Exclusion criteria

Exclusion criteria: (1) Viral hepatitis, Wilson's disease, autoimmune liver disease, drug-induced liver disease and other specific liver diseases that can lead to fatty liver or abnormal liver function (2) Patients with advanced liver cirrhosis, liver cancer and other tumors (3) Patients with lower extremity vascular diseases such as varicose veins of the lower limbs, deep vein thrombosis of the lower extremities (more than 2 points on the Caprini score scale), arterial stenosis of the lower extremities (with symptoms such as intermittent claudication and decreased skin temperature). (4) Patients with fractures or joint strains and sprains within half a year (5) Uncontrolled cardiovascular and cerebrovascular diseases (6) In pregnancy (7) Patients who are on antiviral and anti-tuberculosis therapy (8) Poor blood sugar control (9) Patients with absolute and relative contraindications to cardiopulmonary stress testing ( Absolute contraindications, including: a) Acute myocardial infarction within 2 days; b) unstable angina; c) uncontrolled cardiac arrhythmias, accompanied by symptoms or hemodynamic instability; d) symptomatic severe coarctation of the aorta; e) decompensated heart failure; f) Acute pulmonary embolism; g) acute deep vein thrombosis; h) Acute myocarditis; i) Acute pericarditis; j) Acute aortic dissection; k) Persons with disabilities who pose a safety hazard; l) Psychiatric illness that is unable to communicate. Relative contraindications, including: a) left coronary artery main stenosis; b) valvular heart disease with moderate stenosis; c) electrolyte imbalances; d) elevated blood pressure (resting systolic blood pressure >200 mmHg or diastolic blood pressure > 110 mmHg or both); e) tachycardia; f) bradycardia; g) High-grade atrioventricular block; h) Severe hypertrophic obstructive cardiomyopathy; i) Those who are unable to cooperate with the examination. )

Design outcomes

Primary

MeasureTime frame
proton Density Fat Fraction;

Secondary

MeasureTime frame
magnetic resonance elastography;Alanine aminotransferase;Aspartate aminotransferase;

Countries

China

Contacts

Public ContactXie Ying

Friendship Hospital Affiliated to Capital Medical University

18310601380@163.com+86 183 1060 1380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026